Global Neurostimulation Devices Market, June 2016
Global Neurostimulation Devices Market, June 2016
$4,750.00
The large and burgeoning global market for implantable neurostimulation devices is approaching nearly $4 billion worldwide. Despite lingering economic uncertainty and financial constraints that have affected many other medical device markets, this market is undergoing significant technological advancement due to heavy R&D and investment efforts by dozens of innovative startups and leading medical device companies.
Publisher: MedTech Insight
- Description
- Contents
- Samples
The large and burgeoning global market for implantable neurostimulation devices is approaching nearly $4 billion worldwide. Despite lingering economic uncertainty and financial constraints that have affected many other medical device markets, this market is undergoing significant technological advancement due to heavy R&D and investment efforts by dozens of innovative startups and leading medical device companies. The market is expected to maintain high single-digit growth (under 10%) over the next half-decade, expanding by nearly $2 billion by 2020. A major reason for such optimism is not only the sustained and expanding clinical and commercial success of neurostimulation technologies, but also the ongoing, increasing need for safer and more effective treatments to effectively manage the debilitating, chronic symptoms of many incurable diseases/disorders that negatively affect the quality of life in millions of people worldwide.
Implantable neurostimulation (also commonly termed “neuromodulation”) systems, the focus of this report, typically consist of three implantable components (the extension, lead, and battery/power source) and two external components (the control magnet and a handheld programmer). The extension is used to connect the lead to the power source, and the lead is used to deliver the electrical stimulation to the targeted nerve(s). Neurostimulators may be temporary or permanent, depending on their indication, and are limited by their battery life. Long-life batteries are either self-contained or attached percutaneously on the outside of the body. Some batteries are rechargeable, while others must be replaced periodically.
Neurostimulation implant procedures are minimally invasive, reversible, and have demonstrated substantial success in carefully selected patient populations. Neurostimulation systems have gained credibility in treating intractable chronic pain and other debilitating diseases/disorders, such as drug-refractory epilepsy and Parkinson’s disease, and are expected to achieve even greater acceptance over the next decade due to their ability to provide significant relief to no-option patients who have failed standard medication or more conservative treatment.
This dynamic, new report from Meddevicetracker profiles literally dozens of neurostimulation/neuromodulation devices and emerging technologies covering more than 20 treatment areas. A comprehensive market analysis is provided, including 5-year market forecasts (from 2015-2020) by region (US vs. ROW) and by 6 core therapy segments (deep brain stimulation (DBS), gastric nerve stimulation (GNS), spinal cord stimulation (SCS), sacral nerve stimulation (SNS), vagus nerve stimulation (VNS) and cochlear implants. Market analysis also includes market drivers/limiters, trends, and an in-depth competitive analysis, including 2015 market share by supplier (Global/US/ROW) and detailed corporate strategies for lead competitors.
EXECUTIVE SUMMARY…………………………………………………………………………. ES-1
i. Global Implantable Neurostimulation Devices Market ……………….. ES-4
ii. Methodology……………………………………………………………………….. ES-6
Exhibit ES-1: Estimated U.S. and Global Prevalence of Selected
Neurological Conditions……………………………………………………… ES-2
Exhibit ES-2: 2015, Global Implantable Neurostimulation Devices Market,
Share by U.S. and ROW…………………………………………………….. ES-7
Exhibit ES-3: 2015, Global Implantable Neurostimulation Devices Market,
Estimated Percentage of Sales, by Type of Therapy………………. ES-8
Exhibit ES-4: 2016, Leading Competitors and Products in the Global
Implantable Neurostimulation Devices Market……………………….. ES-9
1. NEUROSTIMULATION TECHNOLOGIES OVERVIEW………………………… 1-1
1.1 Implantable Neurostimulators…………………………………………………… 1-2
1.1.1 Deep Brain Stimulators……………………………………………… 1-7
1.1.2 Gastric Nerve Stimulators………………………………………….. 1-7
1.1.3 Sacral Nerve Stimulators…………………………………………… 1-9
1.1.4 Spinal Cord Stimulators…………………………………………….. 1-9
1.1.5 Vagus Nerve Stimulators…………………………………………. 1-10
1.1.6 Vagal Blocking for Obesity ………………………………………. 1-11
1.1.7 Cochlear Implants ………………………………………………….. 1-12
1.1.8 Retinal Implants……………………………………………………… 1-13
1.2 Noninvasive Peripheral Nerve Stimulation ……………………………….. 1-13
1.3 Transcutaneous Electrical Nerve Stimulation ……………………………. 1-14
1.4 Closed-Loop Stimulation ……………………………………………………….. 1-14
1.5 Hypoglossal Nerve Stimulation……………………………………………….. 1-15
1.6 Transcutaneous Magnetic Stimulation……………………………………… 1-15
1.7 External Trigeminal Nerve Stimulation …………………………………….. 1-15
Exhibit 1-1: Estimated U.S. and Global Prevalence of Selected
Neurological Conditions…………………………………………………………… 1-3
Exhibit 1-2: Selected Advantages and Disadvantages of
Neurostimulation Therapy ……………………………………………………….. 1-5
Exhibit 1-3: Estimated Number of Neurostimulation Implants Implanted,
Worldwide, by Selected Neurological Condition ………………………….. 1-6
Exhibit 1-4: Schematic Illustration of Deep Brain Stimulation…………………………. 1-8
Global Neurostimulation Devices Market Table of Contents
2. NEUROSTIMULATION DEVICES AND COMPETITORS ……………………… 2-1
2.1.1 Alzheimer’s Disease…………………………………………………. 2-2
2.1.1.1 Beijing Pins Medical Co., Ltd……………………….. 2-3
2.1.1.2 The Magstim Company ………………………………. 2-4
2.1.1.3 Functional Neuromodulation Ltd…………………… 2-5
2.1.2 Attention-Deficit/Hyperactivity Disorder ……………………….. 2-7
2.1.2.1 Brainsway…………………………………………………. 2-9
2.1.2.2 NeuroSigma ……………………………………………. 2-10
2.1.3 Autism ………………………………………………………………….. 2-13
2.1.3.1 Brainsway……………………………………………….. 2-13
2.1.3.2 MagVenture A/S………………………………………. 2-14
2.1.4 Blindness………………………………………………………………. 2-15
2.1.4.1 Bionic Vision Australia………………………………. 2-17
2.1.4.2 Pixium Vision…………………………………………… 2-20
2.1.4.3 Retina Implant AG……………………………………. 2-24
2.1.4.4 Second Sight Medical Products………………….. 2-27
2.1.5 Chronic Depression………………………………………………… 2-33
2.1.5.1 Brainsway Ltd………………………………………….. 2-34
2.1.5.2 LivaNova (Cyberonics/Sorin Group)……………. 2-35
2.1.5.3 Fisher Wallace…………………………………………. 2-38
2.1.5.4 MagVenture A/S………………………………………. 2-39
2.1.5.5 Medtronic………………………………………………… 2-42
2.1.5.6 Neuronetics …………………………………………….. 2-45
2.1.5.7 NeuroSigma …………………………………………… 2-49
2.1.5.8 St. Jude Medical………………………………………. 2-50
2.1.6 Chronic Heart Failure ……………………………………………… 2-51
2.1.6.1 BioControl Medical …………………………………… 2-51
2.1.6.2 LivaNova plc (previously Cyberonics/
Sorin Group)……………………………………………. 2-54
2.1.6.3 Medtronic………………………………………………… 2-55
2.1.6.4 St. Jude Medical………………………………………. 2-56
2.1.7 Chronic Migraine Headache……………………………………. 2-58
2.1.7.1 Boston Scientific………………………………………. 2-60
2.1.7.2 Medtronic………………………………………………… 2-60
2.1.7.3 St. Jude Medical………………………………………. 2-61
2.1.7.4 Others (Cluster Headache/Migraine)…………… 2-63
Global Neurostimulation Devices Market Table of Contents
2.1.7.4.1 Autonomic Technologies, Inc….. 2-63
2.1.7.4.2 ElectroCore, LLC ………………….. 2-66
2.1.8 Chronic Pain………………………………………………………….. 2-70
2.1.8.1 Boston Scientific………………………………………. 2-71
2.1.8.2 Medtronic………………………………………………… 2-75
2.1.8.3 St. Jude Medical………………………………………. 2-80
2.1.8.3.1 Neurotherm/St. Jude Medical …. 2-87
2.1.8.4 Others ……………………………………………………. 2-88
2.1.8.4.1 Bioness, Inc. ………………………… 2-90
2.1.8.4.2 Mainstay Medical ………………….. 2-91
2.1.8.4.3 NeuroMetrix …………………………. 2-93
2.1.8.4.4 Neuros Medical…………………….. 2-99
2.1.8.4.5 Nevro Corp…………………………. 2-101
2.1.8.4.5.1 SENZA-RCT
Trial ……………….. 2-105
2.1.8.4.6 Nuvectra Corporation…………… 2-107
2.1.8.4.7 Saluda Medical …………………… 2-110
2.1.8.4.8 SPR Therapeutics……………….. 2-111
2.1.8.4.9 Stimwave, LLC…………………… 2-115
2.1.9 Dystonia, Essential Tremor, and Parkinson’s Disease .. 2-120
2.1.9.1 Boston Scientific…………………………………….. 2-121
2.1.9.2 Medtronic………………………………………………. 2-122
2.1.9.3 St. Jude Medical…………………………………….. 2-128
2.1.9.4 Aleva Therapeutics (and Nuvectra)…………… 2-130
2.1.10 Epilepsy………………………………………………………………. 2-132
2.1.10.1 Beijing Pins Medical Co., Ltd……………………. 2-134
2.1.10.2 Cerbomed GmbH ………………………………….. 2-134
2.1.10.3 CerebralRx/BioControl Medical ………………… 2-137
2.1.10.4 LivaNova plc (previously Cyberonics/
Sorin Group)………………………………………….. 2-138
2.1.10.5 Electrical Geodesics, Inc. ………………………… 2-142
2.1.10.6 Medtronic plc…………………………………………. 2-144
2.1.10.7 NeuroPace ……………………………………………. 2-145
2.1.10.8 NeuroSigma ………………………………………….. 2-148
2.1.10.9 NeuroVista/Cyberonics……………………………. 2-150
2.1.11 Foot Drop …………………………………………………………… 2-153
2.1.11.1 Bioness, Inc…………………………………………… 2-153
Global Neurostimulation Devices Market Table of Contents
2.1.12 Gastro-Esophageal Reflux Disease………………………… 2-154
2.1.12.1 EndoStim………………………………………………. 2-156
2.1.13 Gastroparesis ……………………………………………………… 2-158
2.1.13.1 Medtronic………………………………………………. 2-159
2.1.14 Hearing Loss ……………………………………………………….. 2-161
2.1.14.1 Advanced Bionics AG/Sonova Holding AG … 2-162
2.1.14.2 Cochlear, Ltd…………………………………………. 2-166
2.1.14.3 MED-EL………………………………………………… 2-167
2.1.15 Incontinence………………………………………………………… 2-172
2.1.15.1 Medtronic………………………………………………. 2-172
2.1.15.1.1 NURO System ……………………. 2-176
2.1.15.2 Bioness, Inc…………………………………………… 2-179
2.1.15.3 Cogentix Medical (Uroplasty/
Vision-Sciences)…………………………………….. 2-180
2.1.15.4 Nuvectra Corporation ……………………………… 2-183
2.1.16 Obesity/Diabesity ………………………………………………… 2-183
2.1.16.1 EnteroMedics ……………………………………….. 2-185
2.1.16.2 MetaCure………………………………………………. 2-194
2.1.17 Obsessive-Compulsive Disorder ……………………………. 2-197
2.1.17.1 Medtronic………………………………………………. 2-197
2.1.18 Sleep Apnea……………………………………………………….. 2-198
2.1.18.1 ImThera Medical…………………………………….. 2-200
2.1.18.2 Inspire Medical Systems………………………….. 2-203
2.1.18.3 Respicardia/LivaNova ……………………………. 2-205
2.1.18.4 Others ………………………………………………….. 2-207
2.1.19 Spinal Cord Injury/Paralysis ………………………………….. 2-209
2.1.19.1 BrainGate Research Team………………………. 2-209
2.1.19.2 Synapse Biomedical……………………………….. 2-211
2.1.20 Stroke………………………………………………………………… 2-214
2.1.20.1 MicroTransponder ………………………………….. 2-214
2.1.21 Tinnitus………………………………………………………………. 2-215
2.1.21.1 Brainsway……………………………………………… 2-216
2.1.21.2 Medtronic………………………………………………. 2-216
2.1.21.3 MicroTransponder ………………………………….. 2-217
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Wearables are Transforming R&D and Care Delivery 
Sign up to the